Menu

Generics

10 AA008993

Teva launches enlarged prostate generic in the US

Generics/News | Posted 30/10/2015

Generics giant Teva Pharmaceutical Industries (Teva) announced on 12 October 2015 the exclusive launch of generic dutasteride capsules (0.5 mg) in the US.

picture08

FDA evaluation of excipients in generics

Generics/Research | Posted 23/10/2015

Generics may differ from their reference product in terms of inactive ingredients, e.g. excipients, provided this does not affect the safety and efficacy of the product. Authors from the Office of Generic Drugs at the US Food and Drug Administration (FDA) highlight general toxicology concerns caused by such formulation differences between generic and originator drugs [1].

Patent 1 V13E17

Brand-name drugmakers gain extra days of patent protection

Generics/General | Posted 23/10/2015

Brand-name drugmakers have gained some extra time, be it only days, for protection of their originator drugs after a ruling by the Court of Justice of the European Union clarified the date that drug patents expire.

10 AA008993

ADHD generic receives US FDA approval

Generics/News | Posted 23/10/2015

US generics maker Impax Laboratories (Impax) announced on 21 October 2015 that the company had received approval for its attention deficit hyperactivity disorder (ADHD) guanfacine generic.

04 AA010978

Effectiveness and cost-effectiveness of osteoporosis drugs

Generics/Research | Posted 16/10/2015

Comparison of treatments for osteoporosis has shown that pharmacological intervention for prevention of secondary fractures is cost-effective [1].

Rheumatology.org V13H09

Sanofi launches authorized leflunomide generic in US

Generics/News | Posted 16/10/2015

Sanofi US announced on 1 October 2015 that the company’s US generics division, Winthrop, had launched an authorized generic version of Arava (leflunomide) tablets.

28 MD002360

Impact of antiretroviral generics on the Italian National Health Service

Generics/Research | Posted 09/10/2015

The cost of antiretroviral therapies (ART) for the treatment of human immunodeficiency virus (HIV), which is now considered a chronic disease [1], represents an increasing burden for healthcare services worldwide. In particular, the availability on the market of new antiretroviral drugs, often more effective and more expensive than those available, lead to the need to identify cost containing strategies to ensure the economic sustainability of the healthcare service and to provide effective treatments to patients. Over the next few years, several patents for antiretroviral drugs will expire, giving the possibility for generics to enter the market. The availability of new generics on the market, may lead to a lowering of ART costs, and therefore to the affordability to provide the aforementioned new and innovative drugs.

picture 147

FTC says formula tweaking may be anticompetitive

Generics/General | Posted 09/10/2015

The US Federal Trade Commission (FTC) has come down on the side of generics makers in a case about formula ‘tweaking’ by brand-name drugmakers.

Memantine V14B07

Allergan makes deal with Amneal over its Namenda XR generic

Generics/News | Posted 09/10/2015

Allergan has gained some breathing space for the extended-release version of its blockbuster Alzheimer’s disease treatment Namenda XR (memantine XR) after making a deal to delay generics entry for more than four years.

picture09

Formulation differences between generics and reference products

Generics/Research | Posted 02/10/2015

Authors from the Office of Generic Drugs at the US Food and Drug Administration (FDA) highlight general toxicology concerns caused by formulation differences between generic and originator drugs [1].